March 2016, Vol 6, No 3

Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

By Lisa A. Raedler, PhD, RPh

Medications Used for the Treatment of Multiple Myeloma Associated with ICD-10 Codes

By Kristin A. Esposito, CPhT

ICD Codes, Cancer Drug Coding, Reimbursement

Innovative Approaches to Dispensing Oral Oncolytics in Community Oncology

By Michael J. Reff, RPh, MBA

Measuring Outcomes to Improve Quality

Medicare is poised to incorporate new quality metrics as a guide for payments. At ASH 2015, Helen Burstin, MD, MPH, Chief Scientific Officer, National Quality Forum, Washington, DC, discussed the need for measures and reporting systems that reflect patient care and care coordination. Read More ›

Increased Physical Activity May Help Extend Survival After Prostate Cancer Diagnosis

By Charles Bankhead

Prostate Cancer

Reassuring Practice Patterns in the Use of Curative Treatment for Men with Prostate Cancer

By Phoebe Starr

Prostate Cancer

Idelalisib Improves Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

By Phoebe Starr

Three Ways to Save Taxes While You Invest

By W. Ben, Utley, CFP; Lawrence B. Keller, CFP, CLU, ChFC, RHU, LUTCF

Financial Management, Practice Management

You pay more than your fair share of taxes, so when it comes to your investments, why would you pay more than you absolutely have to? Read More ›

Moonshots and Memos: Looming Changes in Oncology

By Dawn Holcombe, MBA, FACMPE, ACHE

From the Editor

A New Paradigm for Survivorship Care: Assessing the Patient’s Priorities

Page 1 of 2

1
2